Novel mutations in a patient isolate of Streptococcus agalactiae with reduced penicillin susceptibility emerging after long-term oral suppressive therapy

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 6, 2011, Pages 2983-2985

  Longtin, Jean ^a,b   Vermeiren, Christie ^c,d   Shahinas, Dea ^a,d   Tamber, Gurdip Singh ^a,d   McGeer, Allison ^d,e   Low, Donald E ^a,d,e   Katz, Kevin ^c,d,f   Pillai, Dylan R ^a,d  

^a PUBLIC HEALTH ONTARIO   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c Shared Hospital Laboratory   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e MOUNT SINAI HOSPITAL   (Canada)

^f NORTH YORK GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CEFAZOLIN; CEFTRIAXONE; CEMENT; GENTAMICIN; PENICILLIN BINDING PROTEIN; PENICILLIN BINDING PROTEIN 1A; PENICILLIN BINDING PROTEIN 2A; PENICILLIN BINDING PROTEIN 2X; PENICILLIN G; PENICILLIN V POTASSIUM; RNA 16S; UNCLASSIFIED DRUG;

AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL MUTATION; BACTERIUM CULTURE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BLOOD; CASE REPORT; DEBRIDEMENT; GENE MUTATION; GROUP B STREPTOCOCCAL INFECTION; HUMAN; JOINT PROSTHESIS; LIGAND BINDING; LONG TERM CARE; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OSTEOARTHRITIS; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROSTHESIS INFECTION; PROSTHETIC JOINT INFECTION; STREPTOCOCCUS AGALACTIAE; SURGICAL INFECTION; TOTAL HIP PROSTHESIS; TREATMENT DURATION; URINE;

ADMINISTRATION, ORAL; AGED; COMPUTER SIMULATION; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MUTATION; PENICILLIN RESISTANCE; PENICILLIN-BINDING PROTEINS; PENICILLINS; STREPTOCOCCUS AGALACTIAE;

EID: 79956306889     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01243-10     Document Type: Article

References (18)

1. Betriu, C., et al. 1994. Antibiotic resistance and penicillin tolerance in clinical isolates of group B streptococci. Antimicrob. Agents Chemother. 38:2183-2186.
2. CLSI. 2010. Performance standards for antimicrobial susceptibility testing; 20th informational supplement M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA.
3. Dahesh, S., et al. 2008. Point mutation in the group B streptococcal pbp2x gene conferring decreased susceptibility to beta-lactam antibiotics. Antimicrob. Agents Chemother. 52:2915-2918.
4. de Azavedo, J. C., M. McGavin, C. Duncan, D. E. Low, and A. McGeer. 2001. Prevalence and mechanisms of macrolide resistance in invasive and noninvasive group B streptococcus isolates from Ontario, Canada. Antimicrob. Agents Chemother. 45:3504-3508.
5. Edwards, M. S., and C. J. Baker. 2005. Group B streptococcal infections in elderly adults. Clin. Infect. Dis. 41:839-847.
6. Emsley, P., B. Lohkamp, W. G. Scott, and K. Cowtan. 2010. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66:486-501.
7. Gaudreau, C., et al. 2010. Prosthetic hip joint infection with a Streptococcus agalactiae isolate not susceptible to penicillin G and ceftriaxone. J. Antimicrob. Chemother. 65:594-595.
8. Haenni, M., et al. 2010. Penicillin-binding protein gene alterations in Streptococcus uberis isolates presenting decreased susceptibility to penicillin. Antimicrob. Agents Chemother. 54:1140-1145.
9. Hakenbeck, R., T. Grebe, D. Zahner, and J. B. Stock. 1999. Beta-lactam resistance in Streptococcus pneumoniae: penicillin-binding proteins and nonpenicillin-binding proteins. Mol. Microbiol. 33:673-678.
10. Holm, L., and J. Park. 2000. DaliLite workbench for protein structure comparison. Bioinformatics 16:566-567.
11. Jolley, K. A., M. S. Chan, and M. C. Maiden. 2004. mlstdbNet - distributed multi-locus sequence typing (MLST) databases. BMC Bioinformatics 5:86.
12. Jones, A. L., R. H. Needham, A. Clancy, K. M. Knoll, and C. E. Rubens. 2003. Penicillin-binding proteins in Streptococcus agalactiae: a novel mechanism for evasion of immune clearance. Mol. Microbiol. 47:247-256.
13. Kelley, L. A., and M. J. Sternberg. 2009. Protein structure prediction on the Web: a case study using the Phyre server. Nat. Protoc. 4:363-371.
14. Kimura, K., et al. 2008. First molecular characterization of group B streptococci with reduced penicillin susceptibility. Antimicrob. Agents Chemother. 52:2890-2897.
15. Nagano, N., K. Kimura, Y. Nagano, H. Yakumaru, and Y. Arakawa. 2009. Molecular characterization of group B streptococci with reduced penicillin susceptibility recurrently isolated from a sacral decubitus ulcer. J. Antimicrob. Chemother. 64:1326-1328.
16. Nagano, N., et al. 2008. Genetic heterogeneity in pbp genes among clinically isolated group B streptococci with reduced penicillin susceptibility. Antimicrob. Agents Chemother. 52:4258-4267.
17. Schrag, S., R. Gorwitz, K. Fultz-Butts, and A. Schuchat. 2002. Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. MMWR Recomm. Rep. 51:1-22.
18. Zhao, G., T. I. Meier, S. D. Kahl, K. R. Gee, and L. C. Blaszczak. 1999. BOCILLIN FL, a sensitive and commercially available reagent for detection of penicillin-binding proteins. Antimicrob. Agents Chemother. 43:1124-1128.